/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | YARWYarrow Bioscience, I |
|---|---|
| Last close | $15.79close 2026-11-09 |
| Change % | +1.22%close 2026-11-09 |
| Market cap | $42Mclose 2026-11-09 |
| P/E | loss, no P/E |
| Revenue | $570000⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenueFromContractWithCustomerExcludingAssessedTax As of |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | 13.8%FY to 2025-12-31 |
| Net income | $-26483000⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 FilingS-4/A · 0001104659-26-069925 · filed 2026-06-03 Open the filing on EDGAR →Open the XBRL payload →CiteYarrow Bioscience, Inc. (YARW), us-gaap:NetIncomeLoss: -26,483,000 USD, fiscal year ended 2025-12-31. Form S-4/A, accession 0001104659-26-069925, filed 2026-06-03. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001566044/us-gaap/NetIncomeLoss.json |
| Net margin | -4646.1%FY to 2025-12-31 |
| EPS (diluted) | $-0.62⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-12-31 FilingS-4/A · 0001104659-26-069925 · filed 2026-06-03 Open the filing on EDGAR →Open the XBRL payload →CiteYarrow Bioscience, Inc. (YARW), us-gaap:EarningsPerShareDiluted: -0.62 USD per share, fiscal year ended 2025-12-31. Form S-4/A, accession 0001104659-26-069925, filed 2026-06-03. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001566044/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | 3FY to 2025-12-31 |
| Altman Z-ScoreUNVALIDATED | -26.75FY to 2025-12-31 |
| Beneish M-ScoreUNVALIDATED | inputs not filed |
| Next earnings | open now |